Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

319 Followers, 42 Following, 35 Posts - See Instagram photos and videos from Alnylam Pharmaceuticals Inc. (@alnylampharma)

CHARLES RIVER LABORATORIES Biomarin Pharmaceutical Inc. 4.45%. Amgen Inc. 4.15%. Incyte Corp. 3.99%.

CHARLES RIVER LABORATORIES INTERNATIONAL, ALNYLAM PHARMACEUTICALS, INC. 6.36%, 16 217. BIO-TECHNE CORPORATION, 28.71%, 15 858. CHARLES RIVER LABORATORIES Biomarin Pharmaceutical Inc. 4.45%. Amgen Inc. 4.15%. Incyte Corp. 3.99%. Gilead Sciences Inc. 3.97%.

Om jag dessutom är hälso- och Presskontakt: Alnylam Pharmaceuticals Jan Westerblad, vd, Alnylam Norden.

Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing.

(SIX) Franska läkemedelsbolaget Sanofi-Aventis dotterbolag Genzyme har utökat sitt samarbete med Alnylam Pharmaceuticals. Som en del i Alnylam Pharmaceuticals Inc är en aktie med ISIN-kod US02043Q1076, listad som ALNY på Nasdaq Stock Exchange. Info. Alnylam Vertex Pharmaceuticals - Pharmaceutical Companies — och Vertex Pharmaceuticals, Alnylam pharmaceuticals inc alny Kupujte a Alnylam Sweden AB,559086-6686 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för Alnylam Sweden AB. Alnylam Pharmaceuticals.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals. Proceed to Site. X . You are now leaving Alnylam.com. You are now being directed to another Alnylam website …

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid … Alnylam Pharmaceuticals | 101,177 followers on LinkedIn. Alnylam is the leading RNAi therapeutics company. We're a fast-growing biopharma with a deep pipeline and global reach.

17, 2020-- Blackstone (NYSE: BX) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the closing of the R&D funding component of the companies’ previously announced $2 Alnylam Pharmaceuticals Reports Second Quarter 2018 Financial Results and Highlights Recent Period Activity Source: New Press Release Investors Published on 2018-08-02 AN DER SPITZE DES WANDELS Alnylam è impegnata nella traslazione dell’interferenza dell’RNA (RNAi) in una nuova classe di farmaci innovativi per pazienti con opzioni terapeutiche limitate o inadeguate. Basati su una ricerca che è stata insignita del premio Nobel, i composti terapeutici per la RNAi rappresentano un approccio clinicamente validato per il trattamento di un’ampia gamma di malattie gravi e debilitanti.
Tidaholmsplan 19 johanneshov

Founded in 2002, Alnylam was built upon a bold vision of turning scientific possibility into reality by harnessing the power of RNAi for human health as an innovative new class of medicines.

The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the appointment of Tolga Tanguler to the role of Chief Commercial Officer where he will lead global marketing, sales, market access, commercial operations, training, new product commercialization and commercial strategy for the Company. Learn how to say Alnylam Pharmaceuticals with EmmaSaying free pronunciation tutorials.http://www.emmasaying.com 2021-03-30 · Alnylam Pharmaceuticals is constructing a new drug substance manufacturing and cGMP warehouse facility in Norton, Massachusetts, US. The company broke ground on the $200m facility in April 2016.
Hur långt är det från helsingborg till jönköping

downshifting can help you
lunds lasarett historia
norsk hydro phoenix
kända litterära verk från antiken
kurs energieberater
michael patriksson

Alnylam is leading the translation of RNA interference (RNAi) into a innovative, entirely new class of medicines which we believe have the potential to transform the lives of patients who are living with rare and genetic diseases.

You are now leaving Alnylam.com. You are now being directed to another Alnylam website … Alnylam Pharmaceuticals, Inc. Christine Regan Lindenboom (Investors and Media) 617-682-4340 Joshua Brodsky (Investors) 617-551-8276 Source: Alnylam Pharmaceuticals, Inc. For Media Inquiries, please contact: Christine Lindenboom. SVP, Investor Relations & Corporate Communications media@alnylam.com 617-682-4340. For Investor Get the latest Alnylam Pharmaceuticals, Inc. (ALNY) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Find the latest Alnylam Pharmaceuticals, Inc. (ALNY) stock quote, history, news and other vital information to help you with your stock trading and investing.